A Randomised Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG)

Inclusion Criteria: * Male and female patients aged ≥70 yrs identified through the neurooncology MDT. * A histological diagnosis of HGG, either from biopsy or resection. * A life expectancy of \> 2 months * An ECOG performance status of 0/1 * Absolute neutrophil count ≥ 1.5 x 109 * Platelet count ≥ 100 x 109 * Bilirubin ≤ 1.5 mg/dL (or ≤ 25.6 µmol/L) * Creatinine ≤ 2 times upper limit of normal (ULN) * ALT and AST ≤ 4 times ULN * Mini Mental Status Exam score ≥ 17 (Appendix 10) * Written informed consent * Ready to start radiotherapy within 4 weeks of surgery Exclusion Criteria: * Concurrent psoriasis unless the disease is well controlled and patient is under the care of a specialist for the disorder who agrees to monitor for exacerbations * Prior macular degeneration or diabetic retinopathy * Concurrent serious infection or medical illness that would preclude study therapy * Another malignancy within the past 5 years except for curatively treated carcinoma in situ or basal cell carcinoma of the skin * Porphyria * Glucose- 6 phosphate dehydrogenase (G6PD) deficiency * Alcoholic liver disease * Any other concurrent severe/uncontrolled medical conditions * Currently taking amiodarone * Prior radiotherapy, chemotherapy, immunotherapy, biologic agents (e.g., immunotoxins, immunoconjugates, antisense agents, peptide receptor antagonists, interferons, interleukins, tumour-infiltrating lymphocytes, lymphokine-activated killer cell therapy, or gene therapy), or hormonal therapy for brain tumour * Prior polifeprosan 20 with carmustine implant (Gliadel wafer) or GliaSite® brachytherapy * Concurrent cytochrome P450 enzyme-inducing anticonvulsant drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, or oxcarbazepine) * Other concurrent chemotherapeutic or investigational agents for this cancer (Concurrent glucocorticoids will be allowed * Documented side effects to chloroquine or related agents. * Unable to give informed consent * Patients with a history of a psychological illness or condition that in the opinion of the investigator may adversely affect compliance with study medication